Search Results - "Darbonne, W.C"

Activity and safety of ipatasertib (ipat) for AKT activating mutation and/ or PTEN loss/loss of function solid tumors from MyTACTIC by VanderWalde, A., Spigel, D.R., Darbonne, W.C., Yu, W., Kim, Y., Whitehead, Z., Szado, T., Slater, D., Zuniga, R., Arrowsmith, E.

Get full text

355 POSTER Updated safety and efficacy data from a first-in-human, first-in-class, phase I study of Hedgehog pathway antagonist, GDC-0449 by Rudin, C.M, Von Hoff, D.D, LoRusso, P.M, Vernillet, L, Yauch, R, Darbonne, W.C, Mackey, H, de Sauvage, F.J, Low, J.A, Reddy, J.C

Get full text

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer by Liu, J.F., Moore, K.N., Birrer, M.J., Berlin, S., Matulonis, U.A., Infante, J.R., Wolpin, B., Poon, K.A., Firestein, R., Xu, J., Kahn, R., Wang, Y., Wood, K., Darbonne, W.C., Lackner, M.R., Kelley, S.K., Lu, X., Choi, Y.J., Maslyar, D., Humke, E.W., Burris, H.A.

“…MUC16 is a tumor-specific antigen overexpressed in ovarian (OC) and pancreatic (PC) cancers. The antibody–drug conjugate (ADC), DMUC5754A, contains the…”
Get full text

Endothelial Interleukin-8: A Novel Inhibitor of Leukocyte-Endothelial Interactions by Gimbrone, M. A., Obin, M. S., Brock, A. F., Luis, E. A., Hass, P. E., Hébert, C. A., Yip, Y. K., Leung, D. W., Lowe, D. G., Kohr, W. J., Darbonne, W. C., Bechtol, K. B., Baker, J. B.

“…Certain inflammatory stimuli render cultured human vascular endothelial cells hyper-adhesive for neutrophils. This state is transient and reversible, in part…”
Get full text